A combination of fludarabine, pixantrone, dexamethasone, and rituximab (FPD-R) achieved major durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) in a single-arm phase 1 dose-escalation study. The study identified a dose of 120 mg/m2pixantrone as the recommended dose for this regimen. The overall response rate with this regimen was 89%, and the regimen was well tolerated with no grade 3/4 cardiovascular adverse events. Grade 3/4 lymphopenia occurred, however, in 89% of patients and leukopenia in 79%.
Patients with acute myeloid leukemia (AML) receive unnecessarily high-dose levels of chemotherapy, according to Dr Bob Löwenberg, professor of Hematology at the Erasmus University Medical Center in Rotterdam, The Netherlands at the 16th Congress of the European Hematology Association.
Read More ›
Using the recommended dose of 1.3 mg/m2administered as a 3- to 5-second bolus intravenous (IV) injection on days 1, 4, 8, and 11 of 21-day cycles, patients with relapsed multiple myeloma (MM) after 1 to 3 previous lines of therapy achieved noninferior efficacy with subcutaneous versus IV delivery of the drug when receiving up to eight 21-day cycles. In addition, those in the SQ arm experienced improvement in their systemic safety profile.
Multiple myeloma (MM) is a disease with variable presentation, disease trajectory, prognosis, and options for treatment. Integrating the plethora of scientific discovery relative to plasma cell disorders, molecular and cytogenetic attributes and their implications for prognosis and treatment, identification of key components of the bone marrow micro - environment, and the development of novel therapies targeting many of these attributes requires a thorough review of multiple sources of information. Multiple Myeloma: A Textbook for Nurses, edited by Joseph D. Read More ›
The addition of new biomarkers for establishing a prognosis for patients with breast cancer has been recommended in the 2010 edition of the American Joint Committee of Cancer’s Cancer Staging Handbook.1 Human epidermal growth factor receptor type 2 (HER2) status and multigene signature “scores” have been added to estrogen receptor (ER) and progesterone receptor (PR) determinations.1 So, where are we regarding multigene signature scores? Read More ›
Aresearch-based educational program aimed at enhancing communication between non-Hodgkin lymphoma patients and their healthcare providers has just been launched and is available for healthcare providers.
Framing Life With Lymphoma was developed by the Cancer Support Community, which unites The Wellness Community and Gilda’s Club World wide, and was supported by a grant from Cephalon.
CHICAGO—Among patients with chronic myeloid leukemia (CML) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, major molecular response (MMR) rates with nilotinib remain superior to those with imatinib after follow-up extended to a median of 18.5 months. Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
